Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Chinese Patent Office
QuintilesIMS
AstraZeneca
Cipla
Chubb
Teva
Express Scripts
Federal Trade Commission
Cerilliant

Generated: April 26, 2018

DrugPatentWatch Database Preview

Details for Patent: 7,589,079

« Back to Dashboard

Which drugs does patent 7,589,079 protect, and when does it expire?

Patent 7,589,079 protects TYZEKA and is included in one NDA.

This patent has eleven patent family members in seven countries.
Summary for Patent: 7,589,079
Title:Crystalline and amorphous forms of beta-L-2'-deoxythymidine
Abstract:Physical forms of beta-L-2'-deoxythymidine are disclosed that can be characterized by physical appearance, purity levels, Infra-Red and Raman spectroscopy, X-ray powder diffraction patterns, thermal properties, and methods of manufacture. These forms of beta-L-2'-deoxythymidine can be used in the manufacture of other forms of beta-L-2'-deoxythymidine, or in pharmaceutical compositions. Particularly preferred uses are in the treatment of hepatitis B.
Inventor(s): Jonaitis; David (Lafayette, IN), Storer; Richard (Kent, GB)
Assignee: Novartis AG (Basel, CH)
Application Number:11/807,232
Patent Claim Types:
see list of patent claims
Compound; Formulation; Process; Composition; Dosage form; Use;

Drugs Protected by US Patent 7,589,079

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Novartis TYZEKA telbivudine TABLET;ORAL 022011-001 Oct 25, 2006 DISCN Yes No ➤ Sign Up ➤ Sign Up Y Y TREATMENT OF CHRONIC HEPATITIS B IN ADULT PATIENTS ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Non-Orange Book US Patents Family Members for Patent 7,589,079

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
7,323,451 Crystalline and amorphous forms of beta-L-2'-deoxythymidine ➤ Sign Up
7,858,594 Crystalline and amorphous forms of beta-L-2'-deoxythymidine ➤ Sign Up
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

US Army
Cipla
Queensland Health
AstraZeneca
Teva
Fuji
Boehringer Ingelheim
Cantor Fitzgerald
UBS

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.